fbpx

QQQ
+ 0.00
374.98
+ 0%
BTC/USD
-1383.34
64618.07
-2.1%
DIA
-0.02
356.05
-0.01%
SPY
+ 0.01
452.40
+ 0%
TLT
+ 0.00
142.73
+ 0%
GLD
+ 0.01
166.89
+ 0.01%

Analyst Likes Tilray In The Long Run, But Says Stock Is Overvalued Right Now

June 5, 2019 1:56 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Analyst Likes Tilray In The Long Run, But Says Stock Is Overvalued Right Now

Cronos Group Inc (NASDAQ:CRON) and several other cannabis stocks have received some love from Wall Street analysts in the past week, but one analyst said Wednesday the 2019 struggles for Tilray Inc (NASDAQ:TLRY) will continue in the near term.

The Analyst

Oppenheimer analyst Rupesh Parikh initiated coverage of Tilray on Wednesday with a Perform rating and no price target.

The Thesis

Even with Tilray shares down nearly 50 percent year to date, Parikh said it's still hard to justify much upside for the long-term growth stock given its current valuation.

“We look favorably on Tilray’s ability to capitalize on the longer term growth opportunities globally, but we believe the combination of a full valuation and the potential for a slower ramp in Canada given supply shortages in an ‘asset-light model’ limit the potential for outperformance near term,” Parikh wrote in a note.

Need more cannabis news? Check out all of our coverage here.

Parikh said Tilray is bulking up its Canadian business by improving its infrastructure and is adding to its CBD business via acquisitions. In the medical business, Tilray has opportunity to expand into new geographical markets, as well as add new partners.

Another long-term differentiator for Tilray is the company’s top-tier management teams, which Parikh said is one of the best among top cannabis companies. In addition, partnerships with companies like Sandoz, Shoppers Drug Mart, Pharmasave Drugs and Anheuser Busch Inbev NV (NYSE:BUD) bode well for the company’s long-term positioning in key markets.

Unfortunately, Tilray shares trade at about 6.5 times Oppenheimer’s fiscal 2021 sales forecast and about 45 times the firm’s 2021 EBITDA estimate, a valuation that suggests little near-term upside.

Price Action

Tilray shares traded lower by 2.5 percent to $35.63 on Wednesday.

Related Links:

Analyst: Cronos And Altria Make A Powerful Team

Bank Of America Double Upgrades Cronos, Says Bear Thesis 'Increasingly Untenable'

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Nothing Light About Bud's Debt Load

Nothing Light About Bud's Debt Load

One financial metric in the CPG world that stands out to me is Anheuser-Busch InBev's (NYSE: BUD) net debt-to-EBITDA ratio: 4.8x. read more
Monster Beverage Could Be Targeting $3.8B Hard Seltzer Market

Monster Beverage Could Be Targeting $3.8B Hard Seltzer Market

Monster Beverage Corp (NASDAQ: MNST) shares are up 18% in the last three months, and recent rumors have suggested that the company may be planning to launch hard seltzer products in 2021. read more
7 Sin Stocks To Buy During The Coronavirus Shutdown

7 Sin Stocks To Buy During The Coronavirus Shutdown

There’s no question Americans are facing unprecedented stresses these days. Data suggests some Americans are relying on vices such as alcohol, tobacco and cannabis to get through the health crisis. At the same time, gamblers have been driven online for the time being due to casino closures. read more
Goldman Sachs Prefers Diageo Over Anheuser Busch

Goldman Sachs Prefers Diageo Over Anheuser Busch